Sherry Pierce
Tanzania
Research Article
Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction Chemotherapy
Author(s): Fleur Aung, Courtney D DiNardo, Fernando Martinez, Sherry Pierce, Naval Daver, Tapan Kadia, Elias Jabbour, Hagop Kantarjian, Benjamin Lichtiger and Emil J Freireich
Fleur Aung, Courtney D DiNardo, Fernando Martinez, Sherry Pierce, Naval Daver, Tapan Kadia, Elias Jabbour, Hagop Kantarjian, Benjamin Lichtiger and Emil J Freireich
Background: Patients with Acute Myeloid Leukemia (AML) experience profound neutropenia; infections remain the leading cause of morbidity and mortality. Transfusion of functional non-irradiated allogeneic granulocytes may treat or prevent infections in AML patients, and may also have anti-leukemic benefits.
Study Design: Patients free of infection, with a diagnosis of AML or high-risk myelodysplastic syndrome undergoing induction or first-salvage therapy were eligible. Allogeneic Granulocyte Transfusions (GTs) were administered to neutropenic (<0.5 × 109/L) patients every 3-4 days until sustained ANC recovery, initiation of new therapy, or completion of 6 weeks on study.
Results: 45 patients enrolled with a median age of 67 years (range 23-83); 27 (60%) were male. Five patients (11%) never received a GT, du.. View More»
DOI:
10.4172/2155-9864.1000376